Delays As Korea Grapples With Immuno-Oncology Drug Coverage
This article was originally published in PharmAsia News
With some of the new immuno-oncology drugs have already been launched in South Korea, experts are emphasizing the need to rapidly reimburse the innovative and pricey cancer therapies to reduce patients’ financial burden, amid debate over the best way of calculating prices.
You may also be interested in...
Amid repeated calls industry, South Korea decides to pay for Keytruda and Opdivo in its first reimbursement of immuno-oncology drugs, albeit at limited scope. The government is poised to expand reimbursement of IO drugs going forward amid its plan to significantly expand health insurance coverage.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.